AbbVie (ABBV) Competitors $183.51 +0.97 (+0.53%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$183.14 -0.37 (-0.20%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ABBV vs. LLY, JNJ, MRK, PFE, BMY, ZTS, RPRX, CORT, JAZZ, and PRGOShould you be buying AbbVie stock or one of its competitors? The main competitors of AbbVie include Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), and Perrigo (PRGO). These companies are all part of the "pharmaceuticals" industry. AbbVie vs. Eli Lilly and Company Johnson & Johnson Merck & Co., Inc. Pfizer Bristol-Myers Squibb Zoetis Royalty Pharma Corcept Therapeutics Jazz Pharmaceuticals Perrigo AbbVie (NYSE:ABBV) and Eli Lilly and Company (NYSE:LLY) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, community ranking, valuation and institutional ownership. Do analysts rate ABBV or LLY? AbbVie presently has a consensus target price of $210.95, suggesting a potential upside of 14.96%. Eli Lilly and Company has a consensus target price of $1,011.37, suggesting a potential upside of 41.65%. Given Eli Lilly and Company's higher probable upside, analysts clearly believe Eli Lilly and Company is more favorable than AbbVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AbbVie 0 Sell rating(s) 8 Hold rating(s) 17 Buy rating(s) 3 Strong Buy rating(s) 2.82Eli Lilly and Company 1 Sell rating(s) 2 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the MarketBeat Community favor ABBV or LLY? AbbVie received 130 more outperform votes than Eli Lilly and Company when rated by MarketBeat users. Likewise, 73.39% of users gave AbbVie an outperform vote while only 70.64% of users gave Eli Lilly and Company an outperform vote. CompanyUnderperformOutperformAbbVieOutperform Votes135773.39% Underperform Votes49226.61% Eli Lilly and CompanyOutperform Votes122770.64% Underperform Votes51029.36% Does the media refer more to ABBV or LLY? In the previous week, Eli Lilly and Company had 30 more articles in the media than AbbVie. MarketBeat recorded 91 mentions for Eli Lilly and Company and 61 mentions for AbbVie. Eli Lilly and Company's average media sentiment score of 1.16 beat AbbVie's score of 1.06 indicating that Eli Lilly and Company is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 36 Very Positive mention(s) 7 Positive mention(s) 15 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Eli Lilly and Company 70 Very Positive mention(s) 7 Positive mention(s) 11 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, ABBV or LLY? AbbVie has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Eli Lilly and Company has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Is ABBV or LLY more profitable? Eli Lilly and Company has a net margin of 23.51% compared to AbbVie's net margin of 7.59%. AbbVie's return on equity of 296.28% beat Eli Lilly and Company's return on equity.Company Net Margins Return on Equity Return on Assets AbbVie7.59% 296.28% 12.65% Eli Lilly and Company 23.51%85.24%16.19% Do insiders & institutionals have more ownership in ABBV or LLY? 70.2% of AbbVie shares are owned by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are owned by institutional investors. 0.3% of AbbVie shares are owned by company insiders. Comparatively, 0.1% of Eli Lilly and Company shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is ABBV or LLY a better dividend stock? AbbVie pays an annual dividend of $6.56 per share and has a dividend yield of 3.6%. Eli Lilly and Company pays an annual dividend of $6.00 per share and has a dividend yield of 0.8%. AbbVie pays out 279.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Eli Lilly and Company pays out 48.8% of its earnings in the form of a dividend. AbbVie has increased its dividend for 53 consecutive years and Eli Lilly and Company has increased its dividend for 11 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth. Which has stronger valuation & earnings, ABBV or LLY? Eli Lilly and Company has lower revenue, but higher earnings than AbbVie. Eli Lilly and Company is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbbVie$57.37B5.65$4.28B$2.3578.09Eli Lilly and Company$49.00B13.81$10.59B$12.2958.09 SummaryAbbVie beats Eli Lilly and Company on 11 of the 21 factors compared between the two stocks. Get AbbVie News Delivered to You Automatically Sign up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABBV vs. The Competition Export to ExcelMetricAbbViePharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$324.15B$6.46B$5.34B$19.26BDividend Yield3.53%2.63%5.27%3.86%P/E Ratio76.468.4426.9834.42Price / Sales5.65258.46398.8134.89Price / Cash13.5365.8538.3217.51Price / Book96.586.416.774.69Net Income$4.28B$143.95M$3.24B$1.02B7 Day Performance-0.28%0.24%0.27%-2.38%1 Month Performance-1.32%0.37%5.90%4.18%1 Year Performance16.84%0.56%18.83%4.87% AbbVie Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABBVAbbVie4.822 of 5 stars$183.51+0.5%$210.95+15.0%+16.8%$324.15B$57.37B76.4650,000Trending NewsAnalyst DowngradeLLYEli Lilly and Company4.9776 of 5 stars$751.48-0.8%$1,011.37+34.6%-11.6%$712.21B$49.00B64.1739,000Trending NewsAnalyst RevisionJNJJohnson & Johnson4.9507 of 5 stars$152.04+0.5%$170.88+12.4%+4.2%$366.02B$89.33B22.88152,700Trending NewsAnalyst DowngradeMRKMerck & Co., Inc.4.9977 of 5 stars$76.84+1.0%$109.19+42.1%-40.1%$192.95B$63.92B11.4269,000News CoveragePositive NewsAnalyst DowngradePFEPfizer4.9291 of 5 stars$22.95+0.5%$29.17+27.1%-19.2%$130.45B$62.46B16.2783,000Trending NewsBMYBristol-Myers Squibb4.6941 of 5 stars$46.88+0.3%$58.00+23.7%+13.7%$95.39B$47.64B-10.6134,300Positive NewsZTSZoetis4.6047 of 5 stars$163.60+0.3%$212.75+30.0%-4.2%$72.86B$9.29B29.9213,800News CoveragePositive NewsDividend AnnouncementRPRXRoyalty Pharma4.7626 of 5 stars$33.98-0.1%$42.50+25.1%+21.9%$19.59B$2.26B23.4380News CoveragePositive NewsAnalyst DowngradeCORTCorcept Therapeutics4.5122 of 5 stars$74.52-0.8%$138.25+85.5%+185.9%$7.90B$685.45M59.13300News CoveragePositive NewsInsider TradeJAZZJazz Pharmaceuticals4.9121 of 5 stars$109.81+0.8%$182.79+66.5%+1.9%$6.77B$4.06B15.473,200Positive NewsPRGOPerrigo4.6122 of 5 stars$27.10+0.2%$33.00+21.8%-4.9%$3.72B$4.34B-23.158,900News CoveragePositive NewsAnalyst Upgrade Related Companies and Tools Related Companies LLY Competitors JNJ Competitors MRK Competitors PFE Competitors BMY Competitors ZTS Competitors RPRX Competitors CORT Competitors JAZZ Competitors PRGO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ABBV) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbbVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbbVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
